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at baseline compared to the NSAID group. After adjusting for
these factors, no signiﬁcant differences were observed in the rate
of GI events (1% overall), rate of GI medication use (5%) total
health care costs (mean = $1712), or medical costs (mean =
$1513) after 1 year. Prescription drug costs were 38% and 51%
higher for rofecoxib and celecoxib patients respectively com-
pared to the NSAID group (p < 0.0001). CONCLUSION: In
contrast to initial marketing information, in this observational
study, we found no signiﬁcant difference in GI-related outcomes
or total health care costs between the two groups.
PAR7
HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO
PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP:
ASSESSMENT AND IMPACT IN REAL-LIFE CONDITIONS
De Jong R1, Hopman-Rock M2,Tak E1, Klazinga N3
1TNO Quality of Life, Leiden,The Netherlands; 2TNO Quality of
Life/TNO-VU University Medical Center Amsterdam, Leiden,The
Netherlands; 3University Medical Centre, Amsterdam,The
Netherlands
OBJECTIVE: To assess in real-life conditions after previous ran-
domized controlled trials the impact on health care utilization
and expenditure of two self-management programs for older
adults with osteoarthritis (OA) of the knee and hip. METHODS:
Eighteen primary health-care providers were recruited to carry
out a Knee or Hip program. Study participants were older adults
(>55 years) with diagnosed OA of knee or hip. Self-reported data
were collected with pre-test/post-test questionnaires (consulta-
tion of the general practitioner, physiotherapeutic treatment,
consultation of the medical specialist, and use of OA medica-
tion). Pre-test/post-test data of four health insurance companies
were collected on expenditure for physiotherapy and OA med-
ication. RESULTS: Providers delivered 20 Knee and 20 Hip pro-
grams. Background variables of program participants were
comparable with background variables in the RCTs. Signiﬁcant
fewer participants of the Knee program (n = 157) reported
receiving physiotherapy after completion of the program (P =
0.00). In the Hip program (n = 132), the self-reported frequency
of visits to physiotherapists (P = 0.00) and medical specialists (P
= 0.03) decreased. The self-reported use of OA medication had
decreased in both programs (P = 0.00). No effect was observed
for consultations of the general practitioner. The outcomes were
comparable with the outcomes of the RCTs. Expenditure for
physiotherapy and OA medication could not be assessed, due to
difﬁculties in obtaining sufﬁcient reliable data. Expenditure were
not measured in the RCTs. CONCLUSION: Considering the
limitations of the study, both programs indicate ecological valid-
ity as to health care utilization. Compared to the RCTs, the pro-
grams produced similar outcomes in real-life conditions. The
combination of the self-reported reduction in the use of physio-
therapy and the self-reported reduction in the use of OA med-
ication indicate also improved OA symptom control. A guideline
for accurate data collection on OA expenditure is recommended.
Cost-utility and cost-effectiveness analysis is recommended, once
large-scale dissemination in the primary health care system is
realized.
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OBJECTIVES: Non-steroidal anti-inﬂammatory drugs (NSAIDs)
are often used as ﬁrst-line treatment in osteoarthritis (OA). Due
to the increased risk of gastrointestinal (GI) side effects with
NSAIDs, proton pump inhibitors (PPIs) are often prescribed con-
comitantly, but cannot entirely prevent these complications.
Since the combination of the weak opioid tramadol plus parac-
etamol has shown to be an alternative treatment in OA we aimed
to compare the costs of six months’ treatment of OA with
NSAIDs plus PPIs with the tramadol/paracetamol combination
(Zaldiar®) in the Dutch health care setting. METHODS: A cost
comparison of the direct medical costs was appropriate since
both treatments have been shown to be similarly efﬁcacious in
treatment of OA pain of comparable intensity. We combined the
Celecoxib Outcomes Measurement Tool (COMET) for evalua-
tion of cost consequences of NSAIDs plus PPIs with a modiﬁed
model for cost consequences of the tramadol/paracetamol com-
bination presented previously. The NSAIDs under study were
diclofenac and ibuprofen and the PPIs were omeprazole and pan-
toprazole, representing 75% and 85% of the respective market
shares (by units) in The Netherlands. Probabilities were derived
from published literature. Resource utilization data were
obtained from published literature, Delphi panel and ofﬁcial
price and tariff lists (Dutch costing manual). The perspective
taken was that of the health insurance. RESULTS: Costs of six
months’ treatment of OA pain with the tramadol/paracetamol
combinations were €244.45. Savings compared with NSAIDs
plus PPIs treatment were €72.87. Taking into account the rare,
but very cost-consuming, renal side effects of NSAIDs, savings
were €414.79 for six months’ treatment (costs of NSAIDs plus
PPI treatment: €317.32, including renal side effects: €659.24).
Sensitivity analyses conﬁrmed the robustness of the model.
CONCLUSION: The tramadol/paracetamol combination offers
a cost-saving alternative treatment of OA that is not associated
with severe GI or renal complications.
PAR9
A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3
UTILITY SCORES FROM WOMAC INDEX SCORES IN
PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Marshall DA1, Grootendorst P2, Pericak D1, Bellamy N3, Feeny D4,
Gooch K5, Frank C6,Torrance G1
1Innovus Research Inc, Burlington, ON, Canada; 2University of
Toronto,Toronto, ON, Canada; 3University of Queensland, Brisbane,
Queensland, Australia; 4University of Alberta and Institute of Health
Economics, Edmonton, AB, Canada; 5Institute of Health Economics,
Calgary, AB, Canada; 6University of Calgary, Calgary, AB, Canada
OBJECTIVE: To develop a model to translate WOMAC scores
collected in clinical trials of patients with osteoarthritis (OA) into
Health Utilities Index Mark 3 (HUI3) utility scores for applica-
tion in economic evaluation. METHODS: Data from a previ-
ously published open-label randomized controlled trial of
appropriate care with hylan G-F 20 vs. appropriate care without
hylan G-F 20 in 255 outpatients with knee OA. We estimated
linear regression models of HUI3 scores using various functions
of WOMAC, demographics and clinical variables. Out of sample
predictive performance of the models was assessed using the
mean absolute error and several other criteria. RESULTS: The
preferred model included WOMAC pain, stiffness, function sub-
scales, and demographic variables; it accounted for almost 40%
of the variation in the HUI3 utility scores. At the group level,
absolute differences between predicted and actual overall HUI3
utility scores was <0.001 and not statistically signiﬁcantly dif-
ferent from zero. CONCLUSION: A model appropriate for ret-
rospective analyses of data sets in which utility scores were not
collected was developed to estimate HUI3 scores from WOMAC
